Intuitive Surgical, Inc. $ISRG Shares Acquired by Cetera Investment Advisers

Cetera Investment Advisers boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.8% during the 1st quarter, HoldingsChannel reports. The fund owned 120,628 shares of the medical equipment provider’s stock after buying an additional 3,236 shares during the period. Cetera Investment Advisers’ holdings in Intuitive Surgical were worth $55,608,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Norges Bank acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $2,856,987,000. J. Stern & Co. LLP boosted its holdings in shares of Intuitive Surgical by 18,504.6% during the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock worth $1,204,788,000 after purchasing an additional 2,115,814 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Intuitive Surgical by 1,043.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,342,121 shares of the medical equipment provider’s stock valued at $760,124,000 after purchasing an additional 1,224,734 shares in the last quarter. Polen Capital Management LLC bought a new stake in Intuitive Surgical in the fourth quarter worth approximately $477,225,000. Finally, Amundi raised its stake in shares of Intuitive Surgical by 29.7% in the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock valued at $1,451,362,000 after acquiring an additional 739,444 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Iman Jeddi sold 5,625 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the transaction, the senior vice president directly owned 6,463 shares in the company, valued at approximately $2,718,014.65. This represents a 46.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the sale, the executive vice president owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. This represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,169 shares of company stock worth $3,059,135 over the last 90 days. 0.60% of the stock is owned by insiders.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical unveiled a five-layer AI framework for its surgical platforms and demonstrated live telesurgical collaboration, signaling that it is embedding AI into clinical workflows and expanding the capabilities of its robotic surgery ecosystem. Intuitive Surgical (ISRG) Unveils Five Layer AI Plan And Live Telesurgery Demo
• Positive Sentiment: Several analyst-focused pieces framed ISRG as a strong long-term MedTech growth name, highlighting its innovation pipeline, recurring revenue, and high switching costs for surgeons. Why Intuitive Surgical, Inc. (ISRG) is a Top Growth Stock for the Long-Term
• Positive Sentiment: Coverage around Wall Street recommendations continued to describe Intuitive Surgical as a favored investment idea, supporting sentiment around the company’s durable business model. Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?
• Positive Sentiment: CONMED’s expanded AirSeal indication for da Vinci 5 compatibility may help broaden use across Intuitive Surgical’s platform, reinforcing the ecosystem around its robotic systems. CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
• Neutral Sentiment: Intuitive Surgical remains a frequent subject of analyst and stock-report coverage, but these pieces are mostly commentary rather than new fundamentals, so they are unlikely to move the stock on their own. Intuitive Surgical Inc. stock underperforms Thursday when compared to competitors
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares, offering little direct signal for investors.
• Negative Sentiment: Some articles emphasized that ISRG’s shares have pulled back sharply and questioned whether growth expectations in its biggest market are changing, which can weigh on sentiment. Intuitive Surgical Stock Is On Sale, But Is the Growth Story Changing?
• Negative Sentiment: J&J’s progress on Ottava was viewed as a reminder that competition in robotic surgery is intensifying, adding pressure to Intuitive Surgical’s market leadership narrative. J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $337.50 on Friday. The firm has a market capitalization of $119.23 billion, a P/E ratio of 38.66, a P/E/G ratio of 2.40 and a beta of 1.46. The stock has a fifty day moving average price of $406.88 and a two-hundred day moving average price of $459.98. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.32. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ISRG. BMO Capital Markets reissued an “outperform” rating on shares of Intuitive Surgical in a research report on Monday. Barclays set a $651.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. Zacks Research downgraded Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Intuitive Surgical in a research report on Tuesday, May 19th. Finally, JPMorgan Chase & Co. reduced their price objective on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a research report on Friday, July 17th. Twenty-one research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $523.46.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.